Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Expert Opinion on Drug Metabolism & Toxicology|September 3, 2015
Dosing of rivaroxaban by indication: getting the right dose for the patientGines Escolar, Xavier Carne, Eduardo Arellano-Rodrigo
Expert Opinion on Drug Metabolism & Toxicology|January 30, 2014
The pharmacokinetics of edoxaban for the prevention and treatment of venous thromboembolismGines Escolar, Maribel Diaz-Ricart, Eduardo Arellano-Rodrigo, et al.
Leukemia & Lymphoma|October 23, 2002
Idiopathic myelofibrosis associated with ulcerative colitisEduardo Arellano-Rodrigo, Jordi Esteve, Eva Giné, et al.
British Journal of Haematology|June 15, 2005
Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patientsFrancisco Cervantes, Alberto Alvarez-Larrán, Abel Domingo, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|January 6, 2010
Inherited antithrombin deficiency and pregnancy: maternal and fetal outcomesJordi Sabadell, Manel Casellas, Jaume Alijotas-Reig, et al.
Transfusion|August 13, 2015
Acid-base balance disturbances in plasma exchange depend on the replacement fluid usedJoan Cid, Gloria Carbassé, Montse Gamir, et al.
Haematologica|February 8, 2006
Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational statusEduardo Arellano-Rodrigo, Alberto Alvarez-Larrán, Juan Carlos Reverter, et al.
European Journal of Haematology|March 27, 2003
Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphomaEduardo Arellano-Rodrigo, Armando López-Guillermo, Eric M Bessell, et al.
Leukemia & Lymphoma|April 12, 2003
Idiopathic myelofibrosis associated with classic polyarteritis nodosaMireia Camós, Eduardo Arellano-Rodrigo, Deborah Abelló, et al.
Platelets|November 9, 2011
Automated assessment of the neutrophil and platelet activation status in patients with essential thrombocythemiaEduardo Arellano-Rodrigo, Alberto Alvarez-Larrán, Juan Carlos Reverter, et al.
Pageof 5